Royalty Pharma plc (RPRX)
Royalty Pharma buys royalty rights on biopharmaceutical medicines and receives payments tied to those drugs' sales. It last closed at $68.68 on Nov 17, up 0.23% on the day. RPRX reports earnings on Wed, Feb 10, 2027. The average 12-month price target from 3 analysts is $71.00 (+3.4% from the last close), with a high of $78.00 and a low of $67.00. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell). In the past 30 days there were 6 dark pool prints totaling $4.6M, the largest $1.3M.
Key Stats
Last 12 monthsNot reported for this period.
From RPRX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 4). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 3 analysts who set a price target on RPRX in the past 90 days. The average target is $71.00, with a high of $78.00 and a low of $67.00, compared with the last close of $68.68.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Nov 5 | Citigroup | Maintained | Buy | $78 |
| Oct 7 | Morgan Stanley | Maintained | Buy | $67 |
| Sep 8 | TD Cowen | Maintained | Buy | $68 |
| Aug 7 | JP Morgan | Maintained | Buy | $62 |
| Jul 13 | TD Cowen | Maintained | Buy | $65 |
Technical Analysis
The stock is 3% above its 20 day and 10% above its 50 day average. It is 20% above its 200 day average, so the longer trend is still up. Momentum is improving (RSI 67), near overbought. The nearest support is the Pivot at $68.35, and the nearest resistance the Pivot R1 at $69.09.
| RSI (14) | 67.15 | Strong, overbought above 70 | Neutral |
| MACD | 2.22 | Below its signal line | Bearish |
| Stochastic | 73.6 | Middle of its range | Neutral |
| ADX (14) | 38.6 | Trending up | |
| Williams %R | -32.8 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | 60.2 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | +3.4% | Change over 10 sessions | Bullish |
| ATR (14) | $1.55 | Typical daily range, 2.3% of price |
| RSI (14) | 72.26 | Overbought above 70 | Overbought |
| MACD | 4.06 | Above its signal line | Bullish |
| Stochastic | 87.6 | Near the top of its range | Overbought |
| ADX (14) | 43.4 | Strong uptrend | |
| Williams %R | -12.2 | Oversold below −80, overbought above −20 | Overbought |
| CCI (20) | 164.1 | Oversold below −100, overbought above 100 | Overbought |
| Rate of change | +17.2% | Change over 10 sessions | Bullish |
| ATR (14) | $3.11 | Typical daily range, 4.5% of price |
What happened before
See how RPRX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How RPRX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.
Whale Options Flow
90DNo whale options trades in RPRX in the last 90 days.
Dark Pool
30DRPRX Institutional Ownership
Full report →- ▲385 buying vs 267 selling
- ▲Shares held by funds +2.1%
- ▲Funds holding +58
- ▲Superinvestors: 4 added, 1 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 703 | 645 | +9.0% |
| In funds' top 10 | 17 | 14 | +21.4% |
| Held by funds | – | – | – |
| New / increased | 110 / 275 | 97 / 292 | −1.0% |
| Reduced / sold out | 219 / 48 | 175 / 45 | +21.4% |
| Put/call ratio | 68.00 | 0.06 | +110961.5% |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether RPRX is in one of them and how their past RPRX trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered RPRX in an article yet. Here's the latest on the wider market.
RPRX Congress Trades
All congress trades →| Person | Type | Amount | Traded | Filed | Delay |
|---|---|---|---|---|---|
| Donald J TrumpExecutive branch | Other | $1K – $15K | Feb 19, 2026 | May 14, 2026 | 84 d |
| Christopher LandauExecutive branch | Sell | $100K – $250K | Apr 28, 2025 | Jul 16, 2025 | 79 d |
| Ro KhannaD · CA | Buy | $1K – $15K | Nov 14, 2024 | Dec 5, 2024 | 21 d |
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About Royalty Pharma
Royalty Pharma buys royalty rights on biopharmaceutical medicines, so it receives payments based on the sales of those drugs. It is based in New York. Its portfolio covers more than 35 marketed therapies across areas such as rare diseases, neuroscience, oncology, immunology and diabetes, along with some development-stage product candidates. Its customers are drug developers, from small and midsize biotechnology companies and academic or research institutions to large global pharmaceutical companies that sell the medicines.
- Headquarters
- New York, NY







